Literature DB >> 26744593

Are physicians obligated to tell parents about the meningococcal serogroup B vaccine?

Dr Joan L Robinson1.   

Abstract

Entities:  

Year:  2015        PMID: 26744593      PMCID: PMC4692305          DOI: 10.1155/2015/506367

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


× No keyword cloud information.
To the Editor: A recent article argues for inclusion of meningococcal serogroup B vaccine in the routine Ontario immunization schedule (1). Unfortunately, titres to some vaccine components wane significantly over a period as short as 12 months after a primary series, indicating that frequent boosters may be required (2,3). There was only a 16.5% (95% CI 1.5% to 29.2%) decline in carriage rates when university students were immunized (4), potentially yielding less herd effect than with conjugated meningococcal vaccines (5,6). The authors of the article state “… even while the vaccine is not yet included in routine vaccination programs, it remains the responsibility of pediatricians, general practitioners and public health officials to educate and advise parents about the vaccine, enabling them to make informed decisions regarding immunization of their children” (1). The advice from the Canadian Medical Protective Association on this dilemma is: “Whether physicians should inform patients (or in appropriate cases, their legal guardian) about the use of a new vaccine depends on whether administration of the vaccine in the patient’s circumstances is considered to be the standard of care by physicians in the community. A number of factors might be considered in making this determination. If the issue were to come before a Court, the Court might look to standards expressed in accepted medical publications, the common practice of other physicians, and recommendations made by professional bodies or health organizations (such as those mentioned above). Specific circumstances, such as an outbreak of a particular infection, may also influence the standard of care.” I am less convinced than the authors that a recommendation by the Pediatricians of Ontario currently obligates physicians in Ontario to inform all parents about the meningococcal serogroup B vaccine given that other professional organizations, including the National Advisory Committee on Immunization and the Canadian Paediatric Society, have advised waiting for more data before widespread use of this vaccine.
  5 in total

1.  Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.

Authors:  Paul A Kristiansen; Fabien Diomandé; Absatou Ky Ba; Idrissa Sanou; Abdoul-Salam Ouédraogo; Rasmata Ouédraogo; Lassana Sangaré; Denis Kandolo; Flavien Aké; Inger Marie Saga; Thomas A Clark; Lara Misegades; Stacey W Martin; Jennifer Dolan Thomas; Sylvestre R Tiendrebeogo; Musa Hassan-King; Mamoudou H Djingarey; Nancy E Messonnier; Marie-Pierre Préziosi; F Marc Laforce; Dominique A Caugant
Journal:  Clin Infect Dis       Date:  2012-10-19       Impact factor: 9.079

2.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

3.  Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.

Authors:  Timo Vesikari; Roman Prymula; Elizabeth Merrall; Igor Kohl; Daniela Toneatto; Peter M Dull
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

4.  Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

Authors:  Fiona McQuaid; Matthew D Snape; Tessa M John; Sarah Kelly; Hannah Robinson; Ly-Mee Yu; Daniela Toneatto; Diego D'Agostino; Peter M Dull; Andrew J Pollard
Journal:  CMAJ       Date:  2015-03-23       Impact factor: 8.262

5.  The role of pediatricians as key stakeholders in influencing immunization policy decisions for the introduction of meningitis B vaccine in Canada: The Ontario perspective.

Authors:  Hirotaka Yamashiro; Nora Cutcliffe; Simon Dobson; David Fisman; Ronald Gold
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jul-Aug       Impact factor: 2.471

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.